Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the science behind how Tubilis is designing its ADCs differently. He highlights the company's clinical Napi2b and 5T4 programs.
View all episodes
By BiotechTV
4.3
66 ratings
Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the science behind how Tubilis is designing its ADCs differently. He highlights the company's clinical Napi2b and 5T4 programs.
3,223 Listeners
1,917 Listeners
124 Listeners
325 Listeners
61 Listeners
9,948 Listeners
86 Listeners
33 Listeners
353 Listeners
19 Listeners
60 Listeners
510 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners